Analysis of the indications and therapeutic effects of platinib

Pralsetinib, trade name Pralsetinib, is an oral, once-daily, potent and highly selective RET (Rearranged during Transfection) inhibitor. In recent years, it has attracted widespread attention in the field of cancer treatment, especially in the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) and RET mutated medullary thyroid carcinoma (MTC).

1. Indications of platinib

1.RETfusion-positive non-small cell lung cancer (NSCLC): Platinib is approved for the treatment of adult patients with RETfusion-positive locally advanced or metastatic non-small cell lung cancer. These patients often have already received other treatments, such as platinum-based chemotherapy, but their disease has progressed. Platinib can achieve therapeutic purposes by inhibiting the activity of RET kinase and blocking the signal transduction of tumor cell proliferation and growth.

2.RETmutant medullary thyroid cancer (MTC): For patients with advanced or metastatic RETmutant medullary thyroid cancer who require systemic therapy, platinib also shows good therapeutic effects. This type of cancer often does not respond well to traditional chemotherapy drugs, and the emergence of platinib provides these patients with a new treatment option.

3.RETfusion-positive thyroid cancer: In addition to the above two cancers, platinib is also used to treat patients with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine (if radioactive iodine is applicable). These patients have often tried multiple treatments, but their condition has not been effectively controlled. The introduction of platinib has brought hope to these patients.

2. Analysis of the therapeutic effect of platinib

1.High selectivity and potency: Platinib, as a highly selective RET inhibitor, can accurately target RET mutations in tumor cells, thereby reducing damage to normal cells. This high selectivity allows Platinib to exhibit a lower incidence of side effects during treatment, improving patient tolerance and quality of life. At the same time, Platinib also exhibits potent anti-tumor activity and can effectively inhibit the proliferation and metastasis of tumor cells.

2.Significant clinical efficacy: In multiple clinical trials, platinib treatedRETfusion-positiveNSCLC pan>The patient's objective response rate (ORR) and disease control rate (DCR) are significantly better than the efficacy of traditional chemotherapy. For example, in a study of patients with RETfusion-positive NSCLC who had received prior platinum-based chemotherapy, Pratizumab The overall response rate was 57%, with a complete response rate of 5.7%, and the median duration of response has not yet been estimated. These data fully demonstrate the excellent performance of platinib in the treatment of this type of cancer.

3.Good safety and tolerability: The incidence of adverse events of platinib is relatively low, most of which are mild to moderate, and have little impact on patients' quality of life. This is due to its high selectivity and precise targeting properties, which allows the drug to maximize the protection of normal cells while killing tumor cells. As a result, patients generally tolerate platinib well, allowing them to maintain treatment longer.

4. Potential to break through resistance to traditional treatments: It is worth noting that platinib is still effective against some tumor cells that are resistant to traditional chemotherapy or multi-kinase inhibitors. This means that platinib has the potential to be an effective treatment option for tumors that are resistant to specific genetic mutations.